JP2016539083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539083A5 JP2016539083A5 JP2016519326A JP2016519326A JP2016539083A5 JP 2016539083 A5 JP2016539083 A5 JP 2016539083A5 JP 2016519326 A JP2016519326 A JP 2016519326A JP 2016519326 A JP2016519326 A JP 2016519326A JP 2016539083 A5 JP2016539083 A5 JP 2016539083A5
- Authority
- JP
- Japan
- Prior art keywords
- αvβ6
- her2
- inhibitor
- binding agent
- targeted binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361885302P | 2013-10-01 | 2013-10-01 | |
| US61/885,302 | 2013-10-01 | ||
| PCT/EP2014/071028 WO2015049280A1 (en) | 2013-10-01 | 2014-10-01 | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019052035A Division JP2019142876A (ja) | 2013-10-01 | 2019-03-20 | αＶβ６を過剰発現する癌を治療及び診断する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539083A JP2016539083A (ja) | 2016-12-15 |
| JP2016539083A5 true JP2016539083A5 (enExample) | 2017-11-09 |
| JP6527508B2 JP6527508B2 (ja) | 2019-06-05 |
Family
ID=51655742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016519326A Active JP6527508B2 (ja) | 2013-10-01 | 2014-10-01 | αＶβ６を過剰発現する癌を治療及び診断する方法 |
| JP2019052035A Pending JP2019142876A (ja) | 2013-10-01 | 2019-03-20 | αＶβ６を過剰発現する癌を治療及び診断する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019052035A Pending JP2019142876A (ja) | 2013-10-01 | 2019-03-20 | αＶβ６を過剰発現する癌を治療及び診断する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20160319032A1 (enExample) |
| EP (1) | EP3052523B1 (enExample) |
| JP (2) | JP6527508B2 (enExample) |
| CN (1) | CN106232625B (enExample) |
| AU (1) | AU2014331118B2 (enExample) |
| CA (1) | CA2925057A1 (enExample) |
| WO (1) | WO2015049280A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| CN108367049A (zh) * | 2015-12-11 | 2018-08-03 | 海德堡吕布莱希特-卡尔斯大学 | Pkm2调节剂和hmgb1的组合制剂 |
| MX383920B (es) | 2016-05-26 | 2025-03-14 | Recurium Ip Holdings Llc | Compuestos inhibidores de egfr. |
| IL315266A (en) * | 2016-06-14 | 2024-10-01 | Merck Sharp ַ& Dohme Llc | Anti-coagulation factor xi antibodies |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| CN106950371B (zh) * | 2017-02-17 | 2019-03-08 | 张灏 | Pd-l1、cdk5和ctla4中的至少一种在制备肿瘤诊断试剂盒中的用途 |
| MX2019011717A (es) * | 2017-03-31 | 2019-12-16 | Univ California | Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos. |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| EP3873540A4 (en) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| WO2020092839A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| AU2020224164A1 (en) * | 2019-02-22 | 2022-02-10 | Candel Therapeutics, Inc. | GMCI and DDRI combination therapy for treating cancer |
| US11827709B2 (en) | 2019-12-05 | 2023-11-28 | Seagen Inc. | Anti-AVB6 antibodies and antibody-drug conjugates |
| US11579085B2 (en) * | 2020-07-17 | 2023-02-14 | Robert Bosch Gmbh | Sensing devices |
| CN114195893A (zh) * | 2020-09-17 | 2022-03-18 | 百奥泰生物制药股份有限公司 | 抗整联蛋白抗体或抗原结合片段及其应用 |
| CN118440187A (zh) * | 2023-01-05 | 2024-08-06 | 郴州市第一人民医院 | 一种抗SARS-like冠状病毒和/或新冠突变株的广谱抗体及其应用 |
| CN117603348B (zh) * | 2023-11-24 | 2024-08-09 | 优睿赛思(武汉)生物科技有限公司 | 抗新型冠状病毒s蛋白的全人源化抗体及其应用 |
| WO2025163120A1 (en) | 2024-02-01 | 2025-08-07 | Adcytherix Sas | ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY |
| EP4595981A1 (en) * | 2024-02-01 | 2025-08-06 | Jack Elands | Antibody-drug conjugates comprising an anti-integrin v 6 binding antibody |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ535425A (en) * | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
| CN104072614B (zh) * | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
| EP2064244B1 (en) * | 2006-08-03 | 2019-06-05 | MedImmune Limited | ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF |
| SG11201404354UA (en) * | 2012-02-17 | 2014-10-30 | Seattle Genetics Inc | ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER |
-
2014
- 2014-10-01 CA CA2925057A patent/CA2925057A1/en not_active Abandoned
- 2014-10-01 EP EP14777632.2A patent/EP3052523B1/en not_active Not-in-force
- 2014-10-01 AU AU2014331118A patent/AU2014331118B2/en active Active
- 2014-10-01 US US15/026,350 patent/US20160319032A1/en not_active Abandoned
- 2014-10-01 CN CN201480065738.4A patent/CN106232625B/zh active Active
- 2014-10-01 WO PCT/EP2014/071028 patent/WO2015049280A1/en not_active Ceased
- 2014-10-01 JP JP2016519326A patent/JP6527508B2/ja active Active
-
2018
- 2018-11-06 US US16/181,907 patent/US20190389967A1/en not_active Abandoned
-
2019
- 2019-03-20 JP JP2019052035A patent/JP2019142876A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539083A5 (enExample) | ||
| Ahcene Djaballah et al. | HER2 in colorectal cancer: the long and winding road from negative predictive factor to positive actionable target | |
| JP7325463B2 (ja) | がんの予後診断及び治療のための方法及び組成物 | |
| Dean-Colomb et al. | Her2-positive breast cancer: herceptin and beyond | |
| Fayette et al. | Randomized phase II study of duligotuzumab (MEHD7945A) vs. cetuximab in squamous cell carcinoma of the head and neck (MEHGAN Study) | |
| Cohen | Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)-and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC) | |
| Boku | HER2-positive gastric cancer | |
| Viloria-Petit et al. | Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies | |
| Farley et al. | Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study | |
| US20180155429A1 (en) | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody | |
| JP2021524744A (ja) | 分子遺伝子シグネチャーとその使用方法 | |
| Kasper et al. | Targeted therapies in gastroesophageal cancer | |
| JP2022060489A (ja) | ｃ－ＭＡＦの状態に基づく乳がんの治療的処置 | |
| JP2018538274A5 (enExample) | ||
| KR20170094165A (ko) | 화학요법-내성 암을 치료 및 진단하는 조성물 및 방법 | |
| Bonello et al. | Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer | |
| JP2017517507A5 (enExample) | ||
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| JP2020521478A5 (enExample) | ||
| WO2015084808A4 (en) | Identification of predictive biomarkers associated with wnt pathway inhibitors | |
| Shibata et al. | Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells | |
| JP2019501973A5 (enExample) | ||
| Majeed et al. | Gastric carcinoma: recent trends in diagnostic biomarkers and molecular targeted therapies | |
| JP2022519649A (ja) | がんの診断および治療方法 | |
| JP2020522512A5 (enExample) |